{
  "id": 5732286,
  "title": "FDA clears AstraZeneca’s Etcamah for advanced breast cancer",
  "url": "https://urgent.news/2026/09/05/fda-clears-astrazenecas-etcamah-for-advanced-breast-cancer",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-05T04:55:33.000Z",
  "source": {
    "name": "Arabian Post",
    "slug": "arabian-post",
    "url": "https://thearabianpost.com/fda-clears-astrazenecas-etcamah-for-advanced-breast-cancer/"
  },
  "original_language": "en",
  "account": null,
  "summary": "AstraZeneca’s oral breast cancer drug Etcamah has secured accelerated approval from the US Food and Drug Administration for a defined group of patients with advanced disease, despite an earlier negative vote by the regulator’s oncology advisory panel. The FDA authorised Etcamah, or camizestrant, with a CDK4/6 inhibitor for adults with hormone receptor-positive, HER2-negative locally advanced or…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}